The economic value of mismatch repair–guided immunotherapy in endometrial cancer: companion testing and patient selection
Sihan Jing, Yuan He, Yang Liu · 2026
Read The economic value of mismatch repair–guided immunotherapy in endometrial cancer: companion testing and patient selection by Sihan Jing, Yuan He, Yang Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13598390.txt.
Description
Sihan Jing, Yuan He, and Yang Liu present a 2026 review on the economics of gene-guided immunotherapy for endometrial cancer. A tumor's mismatch repair status strongly predicts whether immune drugs will work, so testing can steer expensive treatment toward patients most likely to benefit. The authors review testing routes and the cost-effectiveness studies behind them.
They describe practical pathways built on protein staining, follow-up methylation tests, and selective gene sequencing. Across trials, repair-deficient tumors gained the most quality-adjusted survival and gave the best value per dollar. In repair-normal tumors the case was shakier and hinged on drug prices. The authors frame testing itself as an allocation tool and call for harmonized assays and richer economic models.
Catalog record
| CREATOR | Sihan Jing, Yuan He, Yang Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |